Orexigen to Post Obesity Data in Race With Vivus, Arena

Stock quotes in this article: OREX , VVUS , ARNA  

Results from three other, ongoing phase III studies of Contrave are expected in the middle of the year.

Orexigen is also developing a second weight-loss drug, Empatic, which consists of bupropion and the anti-seizure medicine zonisamide.

Orexigen shares closed up 40 cents, or 6.8%, to $6.29 Tuesday.

  • Loading Comments...
  •  
1 2 3
Next >

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,270.47 1,093.48 2,167.88 34.29
Oil *
75.55
UP
73.00
UP
6.24
UP
18.86
DOWN
0.17
10 Yr
3.43%
SPDR Gold
109.74
+0.72%
+0.57%
+0.88%
-0.49%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services